Price$141.09+0.42 (+0.30%)
01:30 PM07:45 PM
News · 26 weeks65+17%
2026-04-192026-10-11
Mix2590d
- Analyst8(32%)
- Insider5(20%)
- SEC Filings5(20%)
- Other5(20%)
- Earnings2(8%)
Latest news
25 items- PRInsulet Announces Omnipod Discover Now Available in U.S.Web-based data platform turns Omnipod 5 data into clear, personalized insights for users, caregivers, and healthcare professionals Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover turns critical diabetes data into clear visualizations and personalized insights, giving people with diabetes and their HCPs a shared understanding of therapy patterns to make more informed diabetes management decisions. "The future of diabetes ca
- ANALYSTBarclays initiated coverage on Insulet with a new price targetBarclays initiated coverage of Insulet with a rating of Equal Weight and set a new price target of $150.00
- INSIDERSEC Form 4 filed by Insulet Corporation4 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Mazelsky Jonathan Jay was granted 141 shares, increasing direct ownership by 10% to 1,496 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Huffines Robert Luther was granted 178 shares, increasing direct ownership by 7% to 2,627 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- PRInsulet to Announce Third Quarter 2026 Financial Results on November 4, 2026Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (833) 461-5787 for domestic callers, or
- SECInsulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - INSULET CORP (0001145197) (Filer)
- PRInsulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare ForumInsulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod pr
- SECInsulet Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - INSULET CORP (0001145197) (Filer)
- SECInsulet Corporation filed SEC Form 8-K: Leadership Update8-K - INSULET CORP (0001145197) (Filer)
- PRBloomberg 500 (B500) Index Adds Ten Securities Following September ReconstitutionNEW YORK, Aug. 26, 2026 /PRNewswire/ -- Bloomberg Indices announced the following changes to the Bloomberg 500 (B500) Index, effective prior to the open of trading on Thursday, September 10, 2026, to coincide with the September reconstitution of the index. The B500 contains 500 of the most highly capitalized US companies, weighted by float-adjusted market capitalization, representing more than USD 60 trillion in aggregate market capitalization. Ten new firms will enter the index: Revolution Medicines Inc. (RVMD UW Equity), Flex Ltd. (FLEX UW Equity), Credo Technology Group Holding Ltd (CRDO UW Equity), Casey's General Stores In
- PRInsulet to Participate in Wells Fargo 21st Annual Healthcare ConferenceInsulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on Wednesday, September 9, 2026, at 2:15 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnip
- INSIDERPresident and CEO Mcevoy Ashley bought $162,217 worth of shares (1,100 units at $147.47), increasing direct ownership by 5% to 23,731 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Insulet CorporationSCHEDULE 13G/A - INSULET CORP (0001145197) (Subject)
- ANALYSTInsulet downgraded by Truist with a new price targetTruist downgraded Insulet from Buy to Hold and set a new price target of $153.00
- ANALYSTInsulet downgraded by Wells Fargo with a new price targetWells Fargo downgraded Insulet from Overweight to Equal Weight and set a new price target of $144.00
- ANALYSTInsulet downgraded by Analyst with a new price targetAnalyst downgraded Insulet from Overweight to Neutral and set a new price target of $152.00
- ANALYSTInsulet downgraded by BTIG ResearchBTIG Research downgraded Insulet from Buy to Neutral
- ANALYSTInsulet downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Insulet from Outperform to Market Perform and set a new price target of $145.00
- SECSEC Form 10-Q filed by Insulet Corporation10-Q - INSULET CORP (0001145197) (Filer)
- ANALYSTInsulet downgraded by OppenheimerOppenheimer downgraded Insulet from Outperform to Perform
- SECInsulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INSULET CORP (0001145197) (Filer)
- PRInsulet Reports Second Quarter 2026 ResultsSecond Quarter Revenue of $802 million, Increase of 23.5% (22.7% in Constant Currency1) Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended June 30, 2026. Second Quarter Financial Highlights: Revenue of $801.7 million, up 23.5%, or 22.7% in constant currency, and exceeded the high end of the Company’s guidance range of 20% - 22% at constant currency rates Total Omnipod revenue of $795.9 million, rose 24.6%, or 23.8% in constant currency U.S. Omnipod revenue of $544.1 million, increased 20.1% International Omnipod re
- INSIDERSVP, Chief HR Officer Davis Lisa Blair covered exercise/tax liability with 244 shares, decreasing direct ownership by 5% to 4,453 units (SEC Form 4) (withholding tax)4 - INSULET CORP (0001145197) (Issuer)
- ANALYSTUBS resumed coverage on Insulet with a new price targetUBS resumed coverage of Insulet with a rating of Neutral and set a new price target of $174.00
PODD FAQ
7 questionsWhat does Insulet Corporation do?
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.Where does PODD stock trade?
Insulet Corporation (PODD) is listed on NASDAQ.What sector and industry is PODD in?
Insulet Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Insulet Corporation go public?
Insulet Corporation (PODD) completed its IPO in 2007.What are analysts saying about PODD?
Insulet Corporation has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight on 2026-10-07.What companies are similar to PODD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PODD side-by-side with any of them on Quantisnow.How can I track PODD on Quantisnow?
Quantisnow aggregates Insulet Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PODD to receive live email and push alerts on every new disclosure.